Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:514 (10 March), doi:10.1136/bmj.39114.670150.BE (published 19 February 2007)
Martin A Walter, research associate1, Matthias Briel, research associate2, Mirjam Christ-Crain, research associate3, Steen J Bonnema, professor of medicine4, John Connell, professor of endocrinology5, David S Cooper, professor of medicine6, Heiner C Bucher, professor of medicine2, Jan Müller-Brand, professor of nuclear medicine7, Beat Müller, professor of endocrinology3
1 Institute of Nuclear Medicine, University Hospital Basel, Switzerland, and Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, 2 Basel Institute for Clinical Epidemiology, University Hospital Basel, 3 Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, 4 Department of Endocrinology and Metabolism, University Hospital Odense, Denmark, 5 Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, 6 Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, USA, 7 Institute of Nuclear Medicine, University Hospital Basel, Switzerland
Correspondence to: M A Walter m.a.walter{at}gmx.net
Design Meta-analysis.
Data sources Electronic databases (Cochrane central register of controlled trials, Medline, Embase) searched to August 2006 and contact with experts.
Review methods Three reviewers independently assessed trial eligibility and quality. Pooled relative risks for treatment failure and hypothyroidism after radioiodine treatment with and without adjunctive antithyroid drugs were calculated with a random effects model.
Results We identified 14 relevant randomised controlled trials with a total of 1306 participants. Adjunctive antithyroid medication was associated with an increased risk of treatment failure (relative risk 1.28, 95% confidence interval 1.07 to 1.52; P=0.006) and a reduced risk for hypothyroidism (0.68, 0.53 to 0.87; P=0.006) after radioiodine treatment. We found no difference in summary estimates for the different antithyroid drugs or for whether antithyroid drugs were given before or after radioiodine treatment.
Conclusions Antithyroid drugs potentially increase rates of failure and reduce rates of hypothyroidism if they are given in the week before or after radioiodine treatment, respectively.
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+